Search Results - "Kaita, K"

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm by Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balık, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales Jr, F. L., Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., Øvrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B., Estes, C.

“…Summary The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the…”
Get full text

Strategies to manage hepatitis C virus (HCV) disease burden by Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balık, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales Jr, F. L., Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., Øvrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., Gower, E.

“…Summary The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was…”
Get full text

Does SEN-V and other non-A-E hepatotropic viruses contribute to the development and progression of non-alcoholic fatty liver disease? by Grubert Van Iderstine, M., Osiowy, C., Rumbolt, C., Zhang, M., Swidinsky, K., Kaita, K.D.E., Minuk, G.Y.

“…Approximately 10–20% of patients with non-alcoholic fatty liver disease (NAFLD) are at risk of progressing to cirrhosis. The cause of such progression is…”
Get full text

Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy by Sherman, M, Yoshida, E M, Deschenes, M, Krajden, M, Bain, V G, Peltekian, K, Anderson, F, Kaita, K, Simonyi, S, Balshaw, R, Lee, S S

“…Background: The management of patients with chronic hepatitis C who have relapsed or failed to respond to interferon based therapies is an important issue…”
Get full text

Daily Ciprofloxacin Treatment for Patients with Advanced Liver Disease Awaiting Liver Transplantation Reduces Hospitalizations by Minuk, G. Y., Hawkins, K., Kaita, K. D. E., Wong, S., Renner, E., Minuk, L., Uhanova, J.

“…Background Progressive deterioration in liver function is a common cause of hepatic decompensation and indication for liver transplantation in patients with…”
Get full text

ENDURANCE-3: safety and efficacy of glecaprevir/pibrentasvir compared to sofosbuvir plus daclatasvir in treatment-naïve HCV genotype 3-infected patients without cirrhosis by Foster, G.R, Gane, E, Asatryan, A, Asselah, T, Ruane, P.J, Pol, S, Poordad, F, Stedman, C.A, Dore, G, Roberts, S.K, Kaita, K, Vierling, J, Vargas, H.E, Kort, J, Lin, C.-W, Liu, R, Ng, T, Mensa, F

Get full text

mathematical model to study the effect of hepatitis B virus vaccine and antivirus treatment among the Canadian Inuit population by O'Leary, C, Hong, Z, Zhang, F, Dawood, M, Smart, G, Kaita, K, Wu, J

“…The prevalence of hepatitis B among the Canadian Inuit population is 4%. This study will use a mathematical model to compare the roles of vaccination and…”
Get full text

An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C by Patel, K., Benhamou, Y., Yoshida, E. M., Kaita, K. D., Zeuzem, S., Torbenson, M., Pulkstenis, E., Subramanian, G. M., McHutchison, J. G.

“…Noninvasive markers that accurately follow changes in fibrosis may provide alternatives to liver biopsy for assessment of histological endpoints of antiviral…”
Get full text

P724 VIROLOGICAL RESPONSE IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GENOTYPE-1 INFECTION RECEIVING FALDAPREVIR PLUS PEGYLATED INTERFERON a-2a AND RIBAVIRIN IS UNAFFECTED BY RIBAVIRIN DOSE REDUCTION by Asselah, T, Jensen, D.M, Foster, G.R, Sulkowski, M.S, Ouzan, D, Morano, L, Buynak, R, Agarwal, K, Hassanein, T, Forton, D, Cho, M, Genné, D, Kaita, K, Maieron, A, Preotescu, L, Sarrazin, C, Zehnter, E, Streinu-Cercel, A, Stern, J.O, Datsenko, Y, Drulak, M, Voss, F, Quinson, A.-M, Ferenci, P

Get full text

P723 FALDAPREVIR PLUS PEGYLATED INTERFERON/RIBAVIRIN DID NOT INCREASE ANAEMIA COMPARED WITH PEGYLATED INTERFERON/RIBAVIRIN IN HCV GENOTYPE-1, TREATMENT-NAIVE PATIENTS: POOLED ANALYSIS OF PHASE III STUDIES by Asselah, T, Jensen, D.M, Foster, G.R, Sulkowski, M.S, Ouzan, D, Morano, L, Buynak, R, Agarwal, K, Hassanein, T, Forton, D, Negro, F, Genné, D, Kaita, K, Maieron, A, Preotescu, L, Sarrazin, C, Zehnter, E, Romero-Gómez, M, Stern, J.O, Quinson, A.-M, Drulak, M, Garcia, M, Voss, F, Böcher, W, Ferenci, P

Get full text

Patient concerns regarding chronic hepatitis C infections by Minuk, G. Y., Gutkin, A., Wong, S. G., Kaita, K. D. E.

“…Counselling of patients with chronic hepatitis C infections is often limited to discussions regarding how the virus is transmitted and what can be done to…”
Get full text

Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection by Watt, K., Uhanova, J., Gong, Y., Kaita, K., Doucette, K., Pettigrew, N., Minuk, G. Y.

“…Recently, we documented that immunoglobulins stimulate the proliferative activity of rat hepatic stellate cells in vitro. The aim of the present study was to…”
Get full text

31 SAFETY AND ANTIVIRAL ACTIVITY OF THE HCV NON-NUCLEOSIDE POLYMERASE INHIBITOR VX-222 IN TREATMENT-NAIVE GENOTYPE 1 HCV-INFECTED PATIENTS by Rodriguez-Torres, M, Lawitz, E, Conway, B, Kaita, K, Sheikh, A.M, Ghalib, R, Adrover, R, Cooper, C, Silva, M, Rosario, M, Bourgault, B, Proulx, L, McHutchison, J.G

Get full text

Use of Fluoroquinolones in Patients with Chronic Hepatitis C Virus-Induced Liver Failure by KOJIMA, H, KAITA, K. D. E, HAWKINS, K, UHANOVA, J, MINUK, G. Y

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Hepatitis C Infection and Survivals of Liver Transplant Patients in Canada, 1997–2003 by Hong, Z, Smart, G, Dawood, M, Kaita, K, Wen, S.-W, Gomes, J, Wu, J

“…Abstract Introduction Liver transplantation is an important health and health care issue for Canadians. Very few studies have estimated the survival results…”
Get full text

Viral Hepatitis in a Canadian Street-involved Population by Moses, S., Mestery, K., Kaita, K.D.E., Minuk, G.Y.

“…Background: Data on the prevalence and compliance with management of viral hepatitis in the street-involved population are limited. Method: Hepatitis A (HAV),…”
Get full text

Survival Analysis of Liver Transplant Patients in Canada 1997–2002 by Hong, Z., Wu, J., Smart, G., Kaita, K., Wen, S.W., Paton, S., Dawood, M.

“…Liver transplantation is an important health care issue for Canadians. Very few studies have assessed survival and determinants of survival in liver transplant…”
Get full text

Survival Analysis of Liver Transplant Patients with HCV Infection in Canada 1997–2002 by Hong, Z, Dawood, M, Smart, G, Kaita, K, Wen, S.W, Wu, J

“…Purpose Liver transplantation is an important health care issue for Canadians. Very few studies have assessed survival and determinants of survival in liver…”
Get full text

Serum cholesterol and low-density lipoprotein cholesterol levels as predictors of response to interferon therapy for chronic hepatitis C by Minuk, G Y, Weinstein, S, Kaita, K D

Get full text

A multicentre study of the usefulness of liver biopsy in hepatitis C by Bain, V. G., Bonacini, M., Govindarajan, S., Ma, M., Sherman, M., Gibas, A., Cotler, S. J., Deschenes, M., Kaita, K., Jhangri, G. S.

“…The role of liver biopsy in the assessment of chronic hepatitis C is generally accepted yet there is no prospective data available to quantify its…”
Get full text